SOR-C13 in Treating Patients With Advanced Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2022-08-09
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of SOR-C13 in treating patients
with solid tumors that have spread to other places in the body (advanced) and does not
respond to treatment. Drugs used in chemotherapy, such as SOR-C13, work in different ways to
stop the growth of tumor cells, either by killing the cells, by stopping them from dividing,
or by stopping them from spreading.